CannabisNewsBreaks

WednesdayNov 22, 2017 9:28 am

CannabisNewsBreaks – Veritas Pharma Inc.’s (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) CTL Subsidiary Inks Letter of Intent with FDI of Puerto Rico to Initiate Human Trials of CTL-X

Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) recently announced that its 80% owned subsidiary, Cannevert Therapeutics Ltd. ("CTL"), signed a letter of intent with the Fundación de Investigación (“FDI”) in San Juan, Puerto Rico, to conduct the first human study of CTL-X for the treatment of pain. The study of CTL-X, CTL’s lead cannabis strain for pain, will be conducted in two stages to assess the treatment’s analgesic effects. “We are pleased to see Cannevert’s lead strain for pain is finally heading into human trials. It’s important to us to move quickly into this next phase of providing clinical…

Continue Reading

TuesdayNov 21, 2017 12:10 pm

CannabisNewsBreaks – Medical Cannabis Supplier ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Keeps Pricing Competitive

Medical cannabis products distributed by Abcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) in Canada are building on the organic growing environment in any given geographical climate to provide consistent quality while keeping costs down. An article discussing this reads: “As one of Canada’s first licensed cannabis producers, Abcann is significantly ahead of the curve when it comes to production capacities. The company’s Vanluven Facility, producing 1,000 kg annually, is licensed and fully operational, with an additional bloom chamber being added. Construction on the Kimmett facility, an industry-leading, purpose-built, world class style facility, is under contract with another 65 acres under…

Continue Reading

ThursdayNov 16, 2017 9:13 am

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Presenting at Cannabis-Based Science & Medicine Conference

InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) this morning said that it will be presenting twice at the Biopharma Forum on 'Cannabis-Based Science & Medicine' conference. The company will present on Thursday, November 30 and Friday, December 1 at the conference taking place in Denver, CO. The company’s chief scientific officer, Dr. Sazzad Hossain, will be presenting a lecture titled "Epidermolysis to Glaucoma - Identifying Pathology Candidates for Cannabis-Based Treatments." Among other areas of interest, the lecture will shine a light on InMed’s methods of identifying disease targets for cannabinoid compound treatments. To view the full press release, visit http://cnw.fm/9nvGz About…

Continue Reading

WednesdayNov 15, 2017 9:20 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Adds Key Individuals to Board and Executive Team

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) today announced that it has added Mr. Rick Fitzgerald to the Board of Directors and Dr. Michael Bumby to the executive team as Chief Financial Officer. Fitzgerald brings a wealth of strategic marketing and senior leadership experience in the alcoholic beverage and tobacco industries while Bumby adds extensive financial, international and capital markets experience. Paul Lucas, Chair of ABcann’s board of directors, stated, “We are pleased to welcome two outstanding individuals to ABcann and believe their domestic and global business experience will be a significant asset to the Company.” To view the full…

Continue Reading

MondayNov 13, 2017 3:16 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Covered in November ‘Let’s Toke Business’ Report Alongside Canopy Growth (TSX: WEED)

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, has been featured in the November issue of ‘Let’s Toke Business.’ The report draws similarities between Lexaria and Canopy Growth (TSX: WEED), as both companies have had major breakouts on the stock market recently. The ability of Lexaria’s technology to expand into other markets was mentioned in the report, as well the possibility that non-cannabis applications could demonstrate an even greater potential. On November 9, Lexaria announced that it filed a new patent application with the U.S. Patent and Trademark…

Continue Reading

ThursdayNov 09, 2017 10:43 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Filing of New Patent Application with USPTO

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced that it has filed a new patent application with the U.S. Patent and Trademark Office (“USPTO”) covering the use of its DehydraTECH™ technology for the delivery of phosphodiesterase type 5 (PDE5) inhibitors. Existing products occupying this space include Viagra™ (sildenafil) and Cialis™ (tadalafil). Per the update, a common complaint regarding existing PDE5 inhibitors relates to the slow-acting nature of the substances. Lexaria believes that its patented DehydraTECH™ technology, building on existing research with cannabinoid delivery, will…

Continue Reading

ThursdayNov 09, 2017 10:00 am

CannabisNewsBreaks – Wildflower Brands Inc.’s (CSE: SUN) (OTCQB: WLDFF) CBD+ Capsules Featured Amongst Best Products on Hightimes.com Article

Wildflower Brands (CSE: SUN) (OTCQB: WLDFF) was highlighted in an article titled, ‘10 Best CBD Products Of 2017’ authored by Chloé Harper Gold on Hightimes.com. Wildflower's CBD+ Capsules were featured in the article, highlighting the ease of the mess-free capsules which appeals to consumers who seek the full benefit of CBD without the vaporizers. Each capsule contains 30 mg of CBD, amino acids, Omega 3, Omega 6, and hemp-seed oil. The convenience of the capsules makes for a fast and easy approach at incorporating CBD into a daily routine. CBD+ Capsules are available for purchase on the company's website (http://cnw.fm/iDx8v).…

Continue Reading

WednesdayNov 08, 2017 12:53 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Enters the Multibillion-Dollar Tea Market

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed delivery technologies to improve absorption of bioactive compounds and intends to use that technology in the tea market. The company plans to apply its patented DehydraTECH™ technology to supplement a range of black teas with cannabidiol (CBD) from hemp. An article discussing this reads: “Lexaria’s acquisition of Poviva Tea, LLC, announced on November 2 (http://cnw.fm/An29S), gives Lexaria a toehold in this vast $7 billion-plus market and consolidates ownership of Poviva Tea, LLC as a wholly owned Lexaria Bioscience subsidiary. The move also simplifies future operations and certain intellectual property ownership issues.…

Continue Reading

FridayNov 03, 2017 12:16 pm

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Unlocks Ability to Produce 90+ Cannabinoids through Biosynthesis

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) continues to advance its drug development programs through the use of its proprietary bioinformatics database assessment tool. An article discussing this reads: “InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) continues down the fast track with its proprietary technology for the microbial biosynthesis of cannabinoids (http://cnw.fm/hFe3o). The company recently announced it has enabled the production of all four “gateway” cannabinoids using genetically engineered microorganisms. From these gateway substrates, production of all 90+ cannabinoids is possible via biosynthesis. InMed’s breakthrough stands to make the production of cannabis derivatives, including THC, CBD…

Continue Reading

FridayNov 03, 2017 12:14 pm

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Targets Global Cannabis Market

As a licensed producer under the Marijuana for Medical Purposes Regulations in Canada, ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) sells cannabis through its ABcann Medicinals, Inc. subsidiary. “We’re now, hopefully, going to be a global presence,” director Aaron Keay said in an interview with CannabisFN (CFN Media). An article discussing this reads: “ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) director Aaron Keay said in an interview with CannabisFN (CFN Media) that besides achieving greater market share in Canada, ABcann Global also sees opportunities for growth and presence in Western Europe, Germany and South America (http://cnw.fm/3uiqM). The company sells in…

Continue Reading